#1 Clinical Trials Search in Europe

Gad20-209-Fsp-A1

This article discusses ongoing clinical trials investigating the use of Gad20-209-Fsp-A1, a component of the Nous-209 genetic vaccine, in combination with pembrolizumab for treating advanced microsatellite instability-high (MSI-H) colorectal cancer. The trials aim to assess the safety, efficacy, and potential anti-tumor activity of this innovative treatment approach in patients with this specific type of colorectal cancer.

Table of Contents

What is GAD20-209-FSP-A1?

GAD20-209-FSP-A1 is a component of an innovative genetic vaccine called Nous-209, which is being developed to treat certain types of advanced colorectal cancer[1]. This vaccine is part of a group of four similar substances (GAD20-209-FSP-A1, A2, A3, and A4) that work together to potentially stimulate the immune system against cancer cells[1].

How Does It Work?

GAD20-209-FSP-A1 is based on a modified adenovirus, which is a type of virus that has been engineered to deliver genetic material into the body[1]. This genetic material contains instructions for producing Frame Shift Proteins (FSPs), which are abnormal proteins found in certain types of cancer cells[1].

By introducing these FSPs into the body, the vaccine aims to “train” the immune system to recognize and attack cancer cells that produce these abnormal proteins. This approach is known as immunotherapy, as it harnesses the power of the body’s own immune system to fight cancer[1].

Who Might Benefit from This Treatment?

The GAD20-209-FSP-A1 vaccine is being developed for patients with:

  • Locally advanced unresectable or metastatic colorectal cancer: This means cancer that has spread beyond the colon or rectum and cannot be removed surgically[1].
  • Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors: These are specific genetic characteristics of some colorectal cancers that make them potentially more responsive to immunotherapy[1].

Current Clinical Trial

GAD20-209-FSP-A1 is currently being studied in a clinical trial. Here are some key points about the trial:

  • It’s a Phase I/II trial, which means it’s testing both the safety and effectiveness of the treatment[1].
  • The vaccine is being tested in combination with another drug called pembrolizumab, which is an existing immunotherapy treatment[1].
  • The main goal is to see if the combination of the vaccine and pembrolizumab can shrink tumors or slow down cancer growth[1].
  • The trial is also looking at how safe the treatment is and how long its effects last[1].

Potential Benefits

While it’s important to note that the vaccine is still in the testing phase, researchers hope it might offer several potential benefits:

  • It may help the immune system recognize and attack cancer cells more effectively[1].
  • It could potentially shrink tumors or slow down cancer growth in patients with advanced colorectal cancer[1].
  • It might provide a new treatment option for patients whose cancer has specific genetic characteristics (MSI-H or dMMR)[1].

Safety Considerations

As with any medical treatment, especially one in the testing phase, there are important safety considerations:

  • The trial excludes patients with certain health conditions, such as active infections, certain liver diseases, or a history of organ transplants[1].
  • Patients need to have adequate organ function and meet specific health criteria to participate in the trial[1].
  • The treatment may affect fertility, so participants must agree to use effective contraception during and after the treatment[1].
  • As with any immunotherapy, there’s a potential for immune-related side effects, which will be closely monitored during the trial[1].

It’s important to remember that GAD20-209-FSP-A1 is still an experimental treatment. While it shows promise, more research is needed to fully understand its effectiveness and safety. Patients interested in this treatment should discuss it with their healthcare provider to understand if it might be an option for them.

Aspect Details
Drug Name Gad20-209-Fsp-A1 (part of Nous-209 genetic vaccine)
Trial Phase Phase I/II
Target Condition Advanced MSI-H or dMMR Colorectal Cancer
Administration Intramuscular injection
Combination Therapy With pembrolizumab
Primary Endpoint Overall Response Rate (ORR)
Secondary Endpoints Safety, tolerability, Best Overall Response, Duration of Response, Progression-Free Survival
Key Eligibility Criteria Adults with MSI-H/dMMR CRC, adequate organ function, ECOG status 0/1

FAQ

  • What is Gad20-209-Fsp-A1? Gad20-209-Fsp-A1 is one of four components of the Nous-209 genetic vaccine. It is derived from a Great Apes Adenovirus and carries genetic material encoding Frame Shift Peptides (FSPs) that may help stimulate an immune response against cancer cells.
  • What type of cancer is being targeted in these clinical trials? The trials are focusing on locally advanced unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
  • How is Gad20-209-Fsp-A1 administered in the trials? Gad20-209-Fsp-A1 is administered as a solution for injection, typically given intramuscularly (into the muscle).
  • What is the main goal of these clinical trials? The main goal is to assess the preliminary evidence of anti-tumor activity of the vaccination regimen plus pembrolizumab, measured by the overall response rate (ORR) according to RECIST v1.1 criteria.
  • Who is eligible to participate in these trials? Eligible participants include adults (18 years or older) with confirmed MSI-H or dMMR colorectal cancer, adequate organ function, and a life expectancy of at least 6 months. Specific eligibility criteria vary between different cohorts of the study.

Ongoing Clinical Trials on Gad20-209-Fsp-A1

  • Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy Spain

Glossary

  • Microsatellite Instability-High (MSI-H): A condition where cells have a high number of genetic changes (mutations) in certain areas of DNA called microsatellites. This is often associated with defects in the ability to repair DNA mistakes.
  • Mismatch Repair Deficient (dMMR): A condition where cells lack the ability to correct mistakes in DNA during cell division, leading to an accumulation of mutations.
  • Genetic Vaccine: A type of vaccine that uses genetic material (DNA or RNA) to stimulate an immune response against specific targets, such as cancer cells.
  • Frame Shift Peptides (FSPs): Abnormal protein fragments resulting from genetic mutations that cause a shift in the reading frame of DNA, often found in cancer cells.
  • Pembrolizumab: An immunotherapy drug that helps the immune system recognize and attack cancer cells.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Adenovirus: A type of virus that can be modified to carry therapeutic genes into human cells, often used in gene therapy and vaccine development.
  • Intramuscular Injection: A method of administering medication by injecting it directly into a muscle.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.

References

  1. http://clinicaltrials.eu/trial/study-of-nous-209-genetic-vaccine-and-pembrolizumab-for-patients-with-advanced-microsatellite-instability-high-colorectal-cancer/